PMID- 32970188
OWN - NLM
STAT- MEDLINE
DCOM- 20211110
LR  - 20211110
IS  - 1435-1250 (Electronic)
IS  - 0340-1855 (Linking)
VI  - 80
IP  - 9
DP  - 2021 Nov
TI  - Comparative study of the efficacy and safety of tofacitinib, baricitinib, 
      upadacitinib, and filgotinib versus methotrexate for disease-modifying 
      antirheumatic drug-naive patients with rheumatoid arthritis.
PG  - 889-898
LID - 10.1007/s00393-020-00889-x [doi]
AB  - An assessment of the relative efficacy and tolerability of tofacitinib, 
      baricitinib, upadacitinib, and filgotinib compared to those of methotrexate (MTX) 
      was performed in disease-modifying antirheumatic drug (DMARD)-naive patients with 
      rheumatoid arthritis (RA). We performed a Bayesian network meta-analysis to 
      combine direct and indirect evidence from randomized controlled trials (RCTs) so 
      as to examine the efficacy and safety of tofacitinib, baricitinib, upadacitinib, 
      filgotinib, and MTX in DMARD-naive RA patients. Four RCTs comprising 
      2185 patients met the inclusion criteria. The ranking probability based on the 
      surface under the cumulative ranking curve (SUCRA) indicated that upadacitinib 
      15 mg had the highest probability of achieving the American College of 
      Rheumatology 20% (ACR20) response rate, followed by baricitinib 4 mg, tofacitinib 
      5 mg, filgotinib 200 mg, and MTX. Tofacitinib, baricitinib, upadacitinib, and 
      filgotinib treatments achieved significantly higher ACR50 and ACR70 responses 
      compared to MTX. Tofacitinib 5 mg had the highest probability of achieving the 
      ACR50 and ACR70 response rates, followed by upadacitinib 15 mg, baricitinib 4 mg, 
      filgotinib 200 mg, and MTX. The safety analysis based on serious adverse events, 
      adverse events (AEs), and withdrawals due to AEs revealed no statistically 
      significant differences between the respective intervention groups. In 
      conclusion, tofacitinib, baricitinib, upadacitinib, and filgotinib were effective 
      treatment options for DMARD-naive RA patients, suggesting a difference in 
      efficacy and safety among the different JAK inhibitors.
CI  - (c) 2020. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
FAU - Sung, Y-K
AU  - Sung YK
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Korea (Republic of).
FAU - Lee, Y H
AU  - Lee YH
AD  - Department of Rheumatology, Korea University College of Medicine, 73, 
      Goryeodae-ro, 02841, Seongbuk-gu, Seoul, Korea (Republic of). lyhcgh@korea.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
TT  - Vergleichende Studie zur Wirksamkeit und Sicherheit von Tofacitinib, Baricitinib, 
      Upadacitinib und Filgotinib vs. Methotrexat bei DMARD-naiven Patienten mit 
      rheumatoider Arthritis.
DEP - 20200924
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Azetidines)
RN  - 0 (GLPG0634)
RN  - 0 (Heterocyclic Compounds, 3-Ring)
RN  - 0 (Piperidines)
RN  - 0 (Purines)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 0 (Triazoles)
RN  - 4RA0KN46E0 (upadacitinib)
RN  - 87LA6FU830 (tofacitinib)
RN  - ISP4442I3Y (baricitinib)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - *Antirheumatic Agents/adverse effects
MH  - *Arthritis, Rheumatoid/drug therapy
MH  - Azetidines
MH  - Bayes Theorem
MH  - Drug Therapy, Combination
MH  - Heterocyclic Compounds, 3-Ring
MH  - Humans
MH  - Methotrexate/adverse effects
MH  - Piperidines
MH  - Purines
MH  - Pyrazoles
MH  - Pyridines
MH  - Pyrimidines
MH  - Sulfonamides
MH  - Treatment Outcome
MH  - Triazoles
OTO - NOTNLM
OT  - Filgotinib
OT  - JAK inhibitors
OT  - Network meta-analysis
OT  - Rheumatoid arthritis
OT  - Upadacitinib
EDAT- 2020/09/25 06:00
MHDA- 2021/11/11 06:00
CRDT- 2020/09/24 12:13
PHST- 2020/08/30 00:00 [accepted]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/11/11 06:00 [medline]
PHST- 2020/09/24 12:13 [entrez]
AID - 10.1007/s00393-020-00889-x [pii]
AID - 10.1007/s00393-020-00889-x [doi]
PST - ppublish
SO  - Z Rheumatol. 2021 Nov;80(9):889-898. doi: 10.1007/s00393-020-00889-x. Epub 2020 
      Sep 24.